Kite adds industry veterans to leadership team

Kite Pharma has appointed two industry veterans to its leadership team as the Gilead company looks to strengthen its R&D efforts.

Charles Calderaro is joining as Global Head of Technical Operations, while Ken Takeshita has been appointed as Global Head of Clinical Development.

Mr Calderaro will be responsible for leading all aspects of Kite’s technical operations for the company’s commercial and pipeline products.

He joins from BioMarin Pharmaceutical where he currently holds the position of Senior Vice President of Global Manufacturing.

Previous, he was the Vice President of Technical Product Management at Genentech leading the CMC life cycle management of the company’s small molecule product portfolio in Basel, Switzerland.

Dr Takeshita will head Kite’s cell therapy clinical development organisation, including the company’s pipeline in solid tumour research.

He joins Kite from Sorrento Therapeutics, where he is currently Senior Vice President of Clinical Research, responsible for clinical development strategy in oncology.

His previous experience includes many years at Celgene Corporation, where he was Corporate Vice President for Clinical R&D and the Therapeutic Area Head for Lymphoma and CLL.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news